News Releases

News Releases

May 14, 2020

Merus Announces the Acceptance of Six Abstracts at Upcoming Medical Conferences and Provides Program Updates

– MCLA-128, zenocutuzumab, independent epidemiology analysis reaffirms significant clinical and commercial potential in NRG1 fusion cancers – – MCLA-117 demonstrates limited clinical activity in Phase 1 trial – – Extensive panel of novel CD3 bispecific antibodies provides important insights and
May 11, 2020

Merus Announces Financial Results for the First Quarter and Provides Business Update

MCLA-128, zenocutuzumab, Phase 1/2 eNRGy trial remains on track MCLA-117 program update to be presented at upcoming medical meeting Anand Mehra , M.D. to succeed Russell Greig , Ph.D. as Chairman and Paolo Pucci Nominated for Appointment to Merus Board of Directors UTRECHT, The Netherlands and
Mar 12, 2020

Merus Announces Financial Results for the Fourth Quarter and Full Year 2019 and Provides Business Update

UTRECHT, The Netherlands and CAMBRIDGE, Mass. , March 12, 2020 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics TM ), today announced financial results